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Abstract: PURPOSE OF REVIEW The current review presents a concise update on published literature
on donation after circulatory death (DCD) and lung transplantation (LTx). Worldwide an increasing need
for lungs is evident, however the utilization rate of DCD lung donors is still considerably low. In this
summary article, we reviewed both the experimental background and international clinical experience.
RECENT FINDINGS Our analysis confirmed satisfactory results for LTx from DCD donors, which equals
the results from donation after brain death. Although most studies reported on short-term results, some
confirmed these results on the long-term and development of chronic lung allograft dysfunction. Our
review summarizes the different DCD categories and underlines the potential of the DCD V category.
We analyze the barriers to implement a DCD program, discuss the more recent advances like ex-vivo
lung perfusion and describe the future challenges. SUMMARY Based on the current short-term and
long-term clinical results, we believe that barriers for DCD utilization should be overcome, resulting in a
safe implementation of more DCD LTx programs worldwide. VIDEO ABSTRACT.
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Purpose of review
The current review presents a concise update on published literature on donation after circulatory death
(DCD) and lung transplantation (LTx). Worldwide an increasing need for lungs is evident, however the
utilization rate of DCD lung donors is still considerably low. In this summary article, we reviewed both the
experimental background and international clinical experience.
Recent findings
Our analysis confirmed satisfactory results for LTx from DCD donors, which equals the results from donation
after brain death. Although most studies reported on short-term results, some confirmed these results on the
long-term and development of chronic lung allograft dysfunction. Our review summarizes the different DCD
categories and underlines the potential of the DCD V category. We analyze the barriers to implement a DCD
program, discuss the more recent advances like ex-vivo lung perfusion and describe the future challenges.
Summary
Based on the current short-term and long-term clinical results, we believe that barriers for DCD utilization




donation after circulatory death, lung transplantation, organ donation
INTRODUCTION





]. Although the number of lungs trans-
planted per donor reached 0.4, we are still faced with
awaiting-listmortality of 10% – according theOrgan





].Optimizationof thedonorpool should there-
fore be granted priority, leading to an increased inter-
est indonation after circulatory death (DCD) [4–6]. It
was shown that universal identification of potential
DCD donors could increase LTx activity by 50%,
which would result in a virtual elimination of the
waiting-list [7]. Although countries like the United
Kingdom, Australia, Belgium and the Netherlands
reached a high percentage of DCD donors, a contin-
uous global underutilization is noticed [5,8,9]. In
2018, the OPTN reported that only 6.6% (n¼169)
of all LTx (n¼2542) came from DCD, within Euro-
transplantDCDutilization accounted for 5% (n¼62)
of all LTx in 2017 (n¼1233) [10,11]. The latter could
beexplainedbysomecountries (e.g.Germany)which
have no legal framework to allowDCD [12]. Over the
last years, several centers have reported their experi-
ence showing equal short-term and long-term out-
come following LTx when comparing DCD with








In this review article, we summarize the histori-
cal background, definitions and current evidence for
DCD and review the growing clinical experience.
We discuss the recent advances in the field and
future challenges.
HISTORY OF DONATION AFTER
CIRCULATORY DEATH
The first donor used for clinical LTx died from a
myocardial infarction and was a DCD donor [30].
Since then, definitions for brain-death were estab-
lished and only donors whomet brain-death criteria
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were accepted. In 1991, Egan et al. [31] renewed the
interest in the potential of DCD donors with a
canine model of LTx and in 1995 D’Alessandro
et al. reported the first modern and successful LTx
as part of their institutional DCD program [32,33].
In a landmark publication by Steen et al. in 2001 a
successful single-LTx was reported from a donor
after failed cardiac resuscitation, which is defined
as uncontrolled DCD (uDCD) [34], utilizing 17h of
ex-vivo lung perfusion (EVLP) for graft evaluation.
Since then several centers have embraced DCD for
successful expansion of their donor pool.
THE LUNG IS AN AIRBAG FILLED WITH
OXYGEN AND THEREFORE PRIVILEGED
TO SUSTAIN ISCHEMIA
Themain concern regarding DCD is the warm ische-
mic time (WIT) between withdrawal of life-sustain-
ing therapy (WLST) and procurement [6,35,36].
However, it has become apparent that the lungs
are more robust to ischemia than first suspected.
Actually, lung parenchyma is unique among all
organs as it depends not solely on blood supply
for its oxygenation and lung ischemia does not
necessarily equate to tissue hypoxia [37]. In com-
parison with other organs, the lung has relatively
low metabolic needs and is privileged by a local
storage of oxygen in the alveoli. This was confirmed
in a series of canine single-LTx inwhich the lungwas
retrieved at different time points after death and the
contralateral pulmonary artery and bronchus were
ligated after single-LTx, forcing the animals to sur-
vive solely on the transplanted DCD lung [31]. In
another series of rat DCD experiments, it was found
that lung cell death was delayed by postmortem
mechanical ventilation with oxygen [38,39]. In a
series of pig experiments, the Leuven group showed
that up to 60-min WIT with the lung collapsed was
tolerated with a similar graft function as in non-
ischemic lungs [40]. They also showed that preven-
tion of alveolar collapse appears to be the critical
factor in protecting the warm ischemic lung from
reperfusion injury independent of continuous oxy-
gen supply [41]. Recently, it was shown in pigs that
hypoxic cardiac arrest, followed by 60, 90 or 120min
of ischemia and normothermic 4-h EVLP did not
result in differences between the groups regarding
final oxygenation capacity, lung compliance, histo-
logical injury or wet-to-dry ratio, suggesting that
longer WIT alone does not predict worse lung func-
tion [42
&
]. These findings may lead to an expansion
of the acceptable WIT in clinical DCD procedures.
From a biological point of view, it is hypothe-
sized that a briefWIT could even be beneficial due to
the phenomenon of preconditioning [43]. Further-
more, DCD donation exclude the detrimental brain-
death effect, which results in acute lung injury
through a catecholamine storm, hemodynamic
instability and systemic inflammation. It is associ-
ated with increased organ immunogenicity possibly
due to the leukocyte-influx in the allograft [44,45].
DEFINITION OF DONATION AFTER
CIRCULATORY DEATH TIMINGS
The length of acceptable WIT is debatable, although
most centers agree on 60–90min [46
&&
]. In 2008,
Levvey defined WIT as the period between a drop of
SBP less than 50mmHg and pulmonary artery flush.
The International Society for Heart and Lung Trans-
plantation (ISHLT) DCD working group recom-
mended in 2015 six crucial time points in the
DCD process (Fig. 1) [5,20].
The agonal phase is defined as the period
between WLST and death declaration. Most centers
accept a maximal period of 60–90min and up to
180min in Toronto [20]. Apart from a case report
with an agonal phase of 120min, no clinical
research was performed on this topic [47].
Since a recent analysis of the ISHLTDCD registry
on 507 DCD LTx did not show a relationship
between the duration of WIT or the agonal phase
and early survival, the true limits of DCD utilization
may not have been reached. That report showed
that 84% of DCD organs used for LTx reached asys-
tole within 30min and 97% within 60min post
WLST [46
&&
]. To better understand the impact of
these different timings we suggest for future
research to focus on the slope of mean arterial
pressure and saturation and differentiate among
relative, absolute and acirculatory WIT.
DONATION AFTER CIRCULATORY DEATH
CLASSIFICATION
Originally, four DCD categories were defined
according the Maastricht classification (Table 1)
[48].
KEY POINTS
 DCD lung donation cannot be denied in countries with
existing legal framework.
 LTx from controlled DCD donors results in the same
short-term and mid-term outcome as donation after
brain death donors.
 Future research on long-term outcome and a detailed
analysis of the agonal phase is needed.
Lung donation after circulatory death Ceulemans et al.
1087-2418 Copyright  2019 Wolters Kluwer Health, Inc. All rights reserved. www.co-transplantation.com 289
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
The first two represent uDCD donors, the third
and fourth a controlled type of DCD (cDCD). An
uDCD is defined as unexpected death in which the
organs could be considered for transplantation if the
relatives are consented in time and the lungs are
adequately preserved in the body. In case of cDCD
the logistics for procurement, preservation and allo-
cation could be organized in advance [35,36].
Over the years, several subclassifications as well as
a categoryV – donation after euthanasia – were added
(Table 2) [49,50]. The section of the European Society
for Organ Transplantation focusing on Ethical, Legal
and Psychosocial Aspects of organ Transplantation
(ELPAT) deceased donation working group defined
an alternative uncontrolled categoryV as ‘unexpected
circulatory death in critically ill patients’ [51].
CLINICAL EXPERIENCE
Over the last decade, barriers regarding DCD dona-
tion have been overcome by several centers, increas-
ing the worldwide experience.
Table 1. Original Maastricht classification of donation
after circulatory death [48]
Category Definition
Uncontrolled I Death on arrival
II Unsuccessful resuscitation
Controlled III Awaiting cardiac arrest
IV Unexpected cardiac arrest in heart-beating donor
Table 2. Modified Maastricht classification of donation after circulatory death [50]
Category Definition Subclassification
Uncontrolled I Found dead Ia Out-of-hospital
Ib In hospital
II Witnessed cardiac arrest IIa Out-of-hospital
IIb In hospital
Controlled III Planned WLST/expected circulatory death IIIa In ICU
IIIb In OR
IV Cardiac arrest while brain death prior to organ recovery IVa Unexpected in ICU
IVb Expected in OR/ICU
V Medically assisted circulatory death/euthanasia Va Out-of-OR
Vb In OR
ICU, intensive care unit; OR, operating room; WLST, withdrawal of life-sustaining therapy.
FIGURE 1. Schematic illustration of different time points and intervals related to controlled donation after circulatory death
procedure. WLST, withdrawal of life-sustaining therapy.
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Barriers to implement donation after
circulatory death
It remains surprising that DCD LTx implementation
has not found more widespread application. Rea-
sons for this underutilization are multifactorial. The
ISHLT DCD working group reported that 85% of the
participants mentioned complex logistics and
absence of DCD-related protocols as the primary
reasons for not using DCD [52]. Other barriers are
regulations, fear of public disapproval, lack of surgi-
cal expertise, lung quality concerns, declined pre-
mortem evaluation, inability to evaluate lungs in a
controlled fashion, financial challenges and possi-
bility of aborted procurement [53].
We believe that the procedural complexity
should not be overrated; once the ventilation is
restored, perfusion, dissection and preservation
are the same as for DBD. Aborted DCD procurement
– or the so-called dry-run – on the other hand have
been reported to be as high as 40% [19,27]. Although
scoring systems were developed to predict which
patients could potentially become DCD donors, the
scoring efficacy lacks scientific accuracy [27].
Donation after circulatory death lung criteria
and protocols
For DCD donor selection, most centers apply inter-
nationally agreed DBD donor criteria (Table 3).
To further increase the donor pool, centers also
accept more extended-criteria donors (ECD). Proce-
dural criteria on the other hand are center-specific
and might play a decisive role in whether or not to
accept DCD lung allografts. Examples of this are the
location of the WLST (ICU versus operating room),
the comfort therapy administered by the treating
physician, allowed WIT and agonal phase, with-
drawal of tracheal tube, time of reventilation, no-
touch period and EVLP possibility [4,5,54
&
].
Various ethical frameworks for premortemman-
agement are used. In general, it is stated that any
intervention that may accelerate death or cause
potential harm is considered unacceptable. Admin-
istration of heparin is one example. In a DCD pig
model Sanchez et al. showed that premortem hepa-
rin administration did improve EVLP evaluation by
possibly maintaining endothelial homeostasis [55].
In another pig experiment, Keshava et al. [56]
showed no difference in thrombus formation after
flushing of the recovered lungs. To date, no com-
parative clinical study was performed and centers
with or without heparin administration have
reported equally good outcome [20].
More important is the appropriate treatment of
a patient until death. Therefore, we would recom-
mend continuous protective lung ventilation (tidal
volume: 6–8ml/kg ideal body weight, peak end-
expiratory pressure (PEEP): 5–7 cmH2O), perform-
ing adequate bronchoscopy and naso-gastric tube
placement to prevent aspiration.
Clinical experience with uncontrolled
donation after circulatory death
Experience with uDCD has been limited. Major con-
cerns are that the exact length of postmortemWIT is
unknownand thatorgan function cannot be assessed
in advance [5]. Therefore, it is strongly recommended
that the lungs should be properly evaluated with
EVLP to reduce the risk of primary nonfunction
and primary graft dysfunction (PGD) [57].
Currently, Madrid published the largest experi-
ence of 29 cases with an overall hospital mortality of
17% and PGD3 of 38% [58].
Clinical experience with controlled type of
donation after circulatory death
The advantage of a cDCD setting is that premortem
assessment can be performed in the same way as for
DBD, that the WIT is known, that the lungs can be
inspected in situ and preserved in a standard fash-
ion. If theWLST is performed in the operating room,
WIT will remain limited (10–15min). In general,
longer cold ischemic time (CIT) is noticed in DCD
comparedwith DBDdonors. This is explained by the
fact that DCD lungs are accepted after perfusion,
whereas DBD lungs could already be evaluated in
situ before cold flush and anesthesia in the recipient
can already be induced. A second reason is more
particular to Eurotransplant allocation rules, which
state that DCD lungs cannot be offered until 4h
before the procedure. This might create logistical
problems with no operating room available for
the recipient.
Over the last decade, several centers have







]. Inmost reports, data were
compared with DBD. In general, results were excel-
lent with most studies confirming that outcome
after LTx from cDCD is the same as for DBD. We
summarize the largest series in Table 4, describing
Table 3. Standard criteria for lung donation
Age <65 years
Smoking <20 pack years
Chest radiograph clear
Mechanical ventilation <5 days
Blood transfusion <5-U red blood cells
Oxygenation PaO2>300mmHg
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Table 4. Studies reporting on lung transplantation from controlled donation after circulatory death donor
Outcome
PGD % overall patient survival DCD/DBD % CLAD free survival DCD/
DBD
Reference Location Study design DCD/DBD % DCD/% DBD Definition 1-year 3-year 5-year 7-year 10-year 3-year 5-year 7-year
Mason et al. [13] OPTN, USA Multicenter retrospective 36/14903 NR 87/69
Puri et al. [14] St. Louis, Missouri,
USA
Single-center retrospective 11/282 36/NR Grade 3, undefined
timepoint
82/89
De Oliveira et al. [15] Wisconsin,
Wisconson, USA
Single-center retrospective 18/406 33/26 Grade 2 or
3 within 72h
88/88 82/73 82/63 80/75 72/58




Single-center retrospective 35/77 24/25, 9/16, 3/
10 and 6/11





Leuven, Belgium Single-center retrospective 21/154 55/55b, 12/22b,
10/12b
Grade 3 at 0,
24 and 48h
95/91 71/75 70/82b
Zych et al. [18] Harefield, London,
UK
Single-center retrospective 26/131 25/12, 4/6,
4/10, 4/6
Grade 3 at 0,
24, 48 and 72h
89/87 82/75 83/81
Levvey et al. [9] Melbourne, Brisbane,
Perth, Sidney,
Australia





Mason et al. [19] Cleveland, Ohio,
USA
Single-center retrospective 32/573 3/NR, 3/NR,
6/NR, 6/NR
Grade 3 at 0,
24, 48 and 72h
91/NR 71/NR
Cypel et al. [20] ISHLT, DCD registry
(10 centers)
Multicenter retrospective 306d/3992 NR 89/88 61/61









Grade 3 at 0,
24, 48 and 72h
86/84 61/77 51/66e 51/66e 72/88 47/79e 31/59e
Ruttens et al. [23] Leuven, Belgium Single-center retrospective 59/331 44/47 Grade 3 within 72h 87/91 76/83 71/78 82/85 79/68









130/130 8/8 and 8/6 Grade 3 at 48
and 72h
87/82 80/73 69/68 88/88 76/71
Inci et al. [25] Z€urich, Switzerland Single-center retrospective 21/130 26/48, 16/10,
16/14 and 15/14
Grade 3 at 0,






OPTN, USA Multicenter retrospective,
propensity-matched





Single-center retrospective 15/113 40/9c, 13/11,
20/7 and 10/10
Grade 2 or 3 at 0,
24, 48 and 72h
86/92 86/63
Costa et al. [27] New York, New
York, USA
Single-center retrospective 46/237 26/19, 20/19
and 13/17
Grade 3 at
24, 48 and 72h
91/91 78/75
Barbero et al. [28] Papworth,
Cambridge, UK
Single-center retrospectivef 23/163 26/21 and 17/12 Grade 2 or 3 at
24 and 72h
75/82 51/61 82/78 83/42g






Multicenter retrospective 1090/10426 NR 89/88 63/61 59/59 41/39b
CLAD, chronic lung allograft dysfunction; DBD, donation after brain death; DCD, donation after circulatory death; ISHLT, International Society for Heart and Lung Transplantation; NR, not reported; OPTN, Organ
Procurement and Transplantation Network; PGD, primary graft dysfunction.
aOnly two DCD patients at risk.
bEstimated from figure.
cConsidered significant; P less than 0.05.
dIncluding 4% DCD IV and 1% DCD V.
eFive or less DCD patients at risk.
fSurvival analysis in subgroup of bilateral lung transplants (14 DCD and 133 DBD).
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PGD ratio, overall survival and chronic lung allo-
graft dysfunction-free survival.
The significant differences between DCD and
DBD were 5-year patient survival from the Austra-
lian cohort which revealed a 90% survival for the
DCD versus 61% for the DBD cohort [9]; the Boston
experience only showed worse PGD at time 0 for
DCD in comparison with DBD [26
&
]; and Sabashni-
kov et al. showed a shorter bronchiolitis obliterans-
syndrome (BOS)-free survival in the DCD group,
although after 4 years post-transplantation only five
DCD patients were considered at-risk [22]. Further-
more, a meta-analysis revealed no difference
between DBD and DCD LTx in regard to length of
stay, acute rejection or airway complications [4].
The first analysis of the ISHLT DCD registry only
revealed a 2-day longer stay following DCD LTx
(P¼0.016), which was confirmed in the cohort
described by Costa (22 days for DCD versus 18 days
for DBD, P¼0.0014) [20,27]. In 2018, Villavicencio
et al. performed a multivariable regression analysis
of the OPTN data for 25 recipient and donor char-
acteristics, revealing no association between DCD
and increased mortality in comparison with DBD
[26
&
]. In 2016, Sabashnikov et al. reported the lon-
gest follow-up (7 years) comparing DCD with DBD,
concluding that DCD lungs had a predisposition for
developing BOS [22]. However, at 7-year follow-up
only one DCD was included. An update by the
ISHLT DCD registry is expected in 2019, comparing
1090 DCD versus 10426 DBD LTx [29
&&
]. Five-year
patient and BOS-free survival showed no difference
between both groups. In future, more studies ana-
lyzing long-term outcome are needed.
Donation after circulatory death V, following
euthanasia
After the first case of organ donation following
euthanasia in Belgium in 2005, also the Netherlands
and Canada created a legal framework for DCD V
[59,60]. In general, only patients suffering from a
debilitating benign disease like neurological or mus-
cular disorder are considered for organ donation. A
clear separation between the euthanasia request, the
euthanasia procedure and the procurement is of
utmost importance to exclude any conflict of inter-
est between donor and recipient and between the
teams involved. This strict separation is also man-
datory to maintain public trust [60,61].
The first LTx from a DCD V donor was per-
formed in Leuven in 2007 [59]. Until now, 14 double
lungs fromDCDVdonors have been transplanted in
Leuven, representing 12% of the DCD and 2% of the
institutional LTx activity. With more LTx from
DCD V performed in future it will become
interesting to investigate if there is a difference in
outcome between DCD V, DCD III and DBD.
Although donors after euthanasia resemble DCD
III and their organs suffer a period of inevitable
warm ischemia, they are usually not supported on
a ventilator and the mode of death is completely
different compared with ventilator switch-off await-
ing hypoxic cardiac arrest. These donors do not
experience an agonal phase prior to circulatory
arrest as seen in donors dying from hypoxia or from
cardiogenic/hypovolemic shock. There is also no
catecholamine storm as observed in DBD donors.
These benefits could lead to a better outcome.
A recent perspective article explored the ethical
and legal considerations of euthanasia by organ
donation for patients who wish to donate their
organs as in a ‘living organ donation setting’
[62
&
]. This procedure would omit any type of WIT.
Currently no ethical or legal framework is available
to allow this.
EX-VIVO LUNG PERFUSION
Selective use of EVLP is part of the DCD III program
in most centers, however not a prerequisite. In our
opinion, EVLP is not necessary in every case since
excellent results were obtained without the routine
use of EVLP. In the ISHLT 2015 report, only 12% of
the DCD cases underwent normothermic EVLP
[20]. This low percentage may reflect lack of
EVLP-availability at the time of data collection,
but also the perception of each center of the benefit
of EVLP in assessing cDCD. However, these results
have also shown that EVLP is a safe modality with
the potential to increase confidence in DCD lungs
translating to excellent outcomes. Furthermore, we
believe that selective EVLPmay help to better assess
functionally ECD lungs andmayhelp to safely accept
longer agonal phases or expected longer ischemic
times. Possible indications for EVLP may be: PaO2
less than 300mmHg, edematous lungs, massive
blood transfusion (>10U), poor lung compliance,
suspicion of aspiration or pulmonary infection.
In 2017, the University of Alberta reported on
seven successful DCD LTx that underwent portable
normothermic EVLP (OCS Lung, Transmedics, Inc.,
Andover, Massachusetts, USA) [63
&
]. In comparison
with non-DCD lungs, this EVLP cohort had a signif-
icant shorter CIT, a lower PGD grade and higher P : F
ratio at 72h post-transplantation. In 2015, Toronto
compared 28 DCD LTx with EVLP (Toronto EVLP-
system) versus 27 without EVLP, revealing no differ-
ence in survival but a significant shorter hospital
stay for the EVLP group [21]. For uDCD, the results
remain suboptimal and therefore EVLP is strongly
recommended by the ISHLT DCD working group.
Lung donation after circulatory death Ceulemans et al.
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Currently the final reports of two prospective
multicenter clinical trials involving DCD LTx and
EVLP are awaited; first, the aim of the EXPAND Lung
Trial (OCS Lung, Transmedics, Inc.) is to assess the
short-term clinical outcome of lungs from ECD
(including DCD) that were normothermically pre-
served. 79 ECD were included, of which 33% were
DCD LTx [64
&&
]; and second, the NOVEL-extension
trial (XVIVO XPS) aims to evaluate the outcome of
EVLP in case of DCD LTx. 24 DCD-EVLP LTx were
included. In comparison with DBD, there was no
difference in PGD and the survival between




These results confirm that EVLP is a safe plat-
form that may further expand the donor pool by
assessing questionable DCD lungs. EVLP will also
further expand the donor pool as it is an ideal
platform for therapeutic intervention (antibiotic,




AND DONATION AFTER CIRCULATORY
DEATH HEART PROCUREMENT: THE
FUTURE CHALLENGES
The application of extracorporeal circulation tech-
nology to DCD organ retrieval in the form of thor-
aco-abdominal normothermic regional perfusion
(NRP) is believed to make a significant impact
[67
&&
]. In this setting, DCD heart transplantation
has been made possible in synergy with technologi-
cal advances of ex-situ preservation [68
&
]. NRP ena-
bles conversion from a DCD to a DBD-type donor
which offers the opportunity for a dynamic organ
assessment in situ after death declaration and may
lead to expansion of acceptance criteria as well as
creating a window of opportunity for early inter-
ventions. However, this new logistic challenge
should carefully be assessed. Each procurement will
require a detailed discussion between the different
teams about coordination, timings and preservation
strategies.
CONCLUSION
A global implementation of DCD lung donation
would significantly decrease the mortality on the
waiting-list. Over the last 10 years, several centers
and the ISHLT DCD registry reported their expe-
rience, showing that LTx from cDCD results in the
same short-term and mid-term outcome as from
DBD donors. It is advised that EVLP should be
used for uDCD. Future research on EVLP, the
long-term outcome after DCD and a detailed
analysis of the agonal phase are warranted to
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